


Please type a plus sign (+) inside this box → 

CONTINUED PROSECUTION APPLICATION (CPA) REQUEST TRANSMITTAL

Submit an original, and a duplicate for fee processing.

(Only for Continuation or Divisional applications under 37 CFR 1.53(d))

#19
Plunkett
CHECK BOX, if applicable:
 DUPLICATE

Address to:	Assistant Commissioner for Patents Box CPA Washington, DC 20231	Attorney Docket No.	X-10097
		First Named Inventor	Brader, M.L. et al.
		Express Mail Label No.	EL041986835US

This is a request for a continuation or divisional application under 37 CFR 1.53(d), (continued prosecution application (CPA)) of prior application number 08/484542, filed on 7 June 1995, entitled STABILIZED ACYLATED INSULIN FORMULATIONS

NOTES

FILING QUALIFICATIONS: The prior application identified above must be a nonprovisional application that is either: (1) complete as defined by 37 CFR 1.51(b), or (2) the national stage of an international application in compliance with 35 U.S.C. 371.

C-I-P NOT PERMITTED: A continuation-in-part application cannot be filed as a CPA under 37 CFR 1.53(d), but must be filed under 37 CFR 1.53(b).

EXPRESS ABANDONMENT OF PRIOR APPLICATION: The filing of this CPA is a request to expressly abandon the prior application as of the filing date of the request for a CPA. 37 CFR 1.53(b) must be used to file a continuation, divisional, or continuation-in-part of an application that is not to be abandoned.

ACCESS TO PRIOR APPLICATION: The filing of this CPA will be construed to include a waiver of confidentiality by the applicant under 35 U.S.C. 122 to the extent that any member of the public who is entitled under the provisions of 37 CFR 1.14 to access to, copies of, or information concerning, the prior application may be given similar access to, copies of, or similar information concerning, the other application or applications in the file jacket.

35 U.S.C. 120 STATEMENT: In a CPA, no reference to the prior application is needed in the first sentence of the specification and none should be submitted. If a sentence referencing the prior application is submitted, it will not be entered. A request for a CPA is the specific reference required by 35 U.S.C. 120 and to every application assigned the application number identified in such request, 37 CFR 1.78(a).

1. Enter the unentered amendment previously filed on under 37 CFR 1.116 in the prior nonprovisional application.
2. A preliminary amendment is enclosed.
3. This application is filed by fewer than all the inventors named in the prior application, 37 CFR 1.53(d)(4).
 - a. **DELETE** the following inventor(s) named in the prior nonprovisional application:
 - b. The inventor(s) to be deleted are set forth on a separate sheet attached hereto.
4. A new power of attorney or authorization of agent (PTO/SB/81) is enclosed.
5. Information Disclosure Statement (IDS) is enclosed:
 - a. PTO-1449
 - b. Copies of IDS Citations

BEST AVAILABLE COPY

12/21/1999 DVUONG 00000129 050840 08484542

01 FC:131 760.00 CH

See fuel ANDT FOR LIST OF TIME fees

Please type a plus sign (+) inside this box →

CLAIMS	(1) FOR	(2) NUMBER FILED	(3) NUMBER EXTRA	(4) RATE	(5) CALCULATIONS
	TOTAL CLAIMS (37 CFR 1.16(c))	<u>10</u> - 20 =	<u>0</u>	x\$ 18.00=	\$0
	INDEPENDENT CLAIMS (37 CFR 1.16(b))	1 - 3 =	0	x\$ 78.00=	0
	MULTIPLE DEPENDENT CLAIMS (if applicable) (37 CFR 1.16(d))			+\$ _____ =	0
				BASIC FEE (37 CFR 1.16(a))	\$ 760.00
			Total of above Calculations=		\$760.00
	Reduction by 50% for filing by small entity (Note 37 CFR 1.9, 1.27, 1.28).				
				TOTAL =	\$760.00

6. Small entity status:
- a. A small entity statement is enclosed.
 - b. A small entity statement was filed in the prior nonprovisional application and such status is still proper and desired.
 - c. Is no longer claimed.
7. The Commissioner is hereby authorized to credit overpayments or charge the following fees to Deposit Account No. 05-0840:
- a. Fees required under 37 CFR 1.16.
 - b. Fees required under 37 CFR 1.17.
 - c. Fees required under 37 CFR 1.18.
8. A check in the amount of \$ _____ is enclosed.
9. Other: _____


NOTE: The prior application's correspondence address will carry over to this CPA UNLESS a new correspondence address is provided below.

10. NEW CORRESPONDENCE ADDRESS

<input type="checkbox"/>	Customer Number or Bar Code Label (Insert Customer No. Or Attach bar code label here)	<input type="checkbox"/>	Correspondence address below
--------------------------	--	--------------------------	------------------------------

NAME	James J. Kelley		
	Eli Lilly and Company		
ADDRESS	Lilly Corporate Center		
	Patent Division DC: 1104		
CITY	Indianapolis	STATE	Indiana
COUNTRY	U.S.A.	TELEPHONE	317-277-8110
			FAX
			317-276-5172

11. SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED

NAME	JAMES J. KELLEY		
SIGNATURE			
DATE	17 December 1999		

BEST AVAILABLE COPY

"Express Mail" mailing label number	EL041986835US
Date of Deposit	17 December 1999
I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Assistant Commissioner of Patents, Washington, D.C. 20231.	
Printed Name	

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

C I P E
P A T E N T & T R A D E M A R K O F F I C E
FEE TRANSMITTALEffective November 10, 1997.
Patent fees are subject to annual revision.

TOTAL AMOUNT OF PAYMENT \$1,850.00

METHOD OF PAYMENT (check one)

1. The Commissioner is hereby authorized to charge indicated fees and credit any overpayments to:

Deposit Account Number
Deposit Account Name

05-0840

Eli Lilly and Company

- Charge Any Additional Fee Required Under 37 CFR 1.16 and 1.17 Charge the Issue Fee Set in 37 CFR 1.18 at the Mailing of the Notice of Allowance

2. Payment Enclosed: Check Money Order Other

FEE CALCULATION

1. FILING FEE

Large Fee Code	Entity Fee (\$)	Small Fee Code	Entity Fee (\$)	Fee Description	Fee Paid
101	760	201	380	Utility filing fee	
106	310	206	155	Design filing fee	
107	480	207	240	Plant filing fee	
108	760	208	380	Reissue filing fee	
114	150	214	75	Provisional filing fee	

SUBTOTAL (1) -0-

2. CLAIMS		Extra	Fee from below	Fee Paid
Total Claims	-20=		X 18	=
Independent Claims	-3=		X 78	=
Multiple Dependent Claims			X 260	=

Large Fee Code	Entity Fee (\$)	Small Fee Code	Entity Fee (\$)	Fee Description
103	18	203	9	Claims in excess of 20
102	78	202	39	Independent claims in excess of 3
104	260	204	130	Multiple dependent claim
109	78	209	39	Reissue independent claims over original patent
110	18	210	9	Reissue claims in excess of 20 and over original patent

SUBTOTAL (2) -0-

*Reduced by Basic Filing Fee Paid

SUBTOTAL (3) \$1,850.00

SUBMITTED BY

Typed or Printed Name

Signature

"Express Mail" mailing label number

EL04198683SUS

Date of Deposit 17 December 1999

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Assistant Commissioner of Patents, Washington, D.C. 20231.

Devota J. Sheffield

Printed Name

Devota J. Sheffield
Signature

Complete (if applicable)

Reg. Number 41,888

Date 17 December 1999



201 C
Plunkett
211910

"Express Mail" mailing label number EL041986835US

Date of Deposit 17 December 1999

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Devota J. Sheffield
Printed Name

Devota J. Sheffield
Signature

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants	:	Brader, et al.)	
Serial No.	:	08/484,542)	Group Art Unit:
Filed	:	7 June 1995)	1645
For	:	Stabilized Acylated Insulin Formulations)	Examiner: Allen, M.
Docket No.	:	X-10097)	

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents
Washington, D. C. 20231

BEST AVAILABLE COPY

Sir:

This Preliminary Amendment accompanies a Continued Prosecution Application under 37 CFR §1.53(d) and a petition for an extension of time under 37 C.F.R. §1.136(a). The petition authorizes the Office to charge the fee for a five-month extension under 37 C.F.R. §1.17 to Deposit Account No. 05-0840 in the name of Eli Lilly and Company.

Claims 25-55 and pending and are rejected finally (17 November 1998). Applicants filed a Notice of Appeal on 17 May 1999.

Please amend the accompanying application as

12/21/1999 DVUONG 00000129 050840 08484542
02 FC:128 1850.00 CH